Opportunity Information: Apply for RFA HL 27 009
The funding opportunity titled "Single Source: HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials - Data Translation Center (U54 Clinical Trial Optional)" is a National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) Notice of Funding Opportunity (NOFO) that supports the continuation of HeartShare, an ongoing NHLBI phenomics program focused on heart failure with preserved ejection fraction (HFpEF). The central goal is to refine HFpEF subtypes and identify treatment targets that can be used to design and run more personalized, subtype-informed clinical trials. The award mechanism is a U54 cooperative agreement, meaning NHLBI will have substantial involvement in project oversight and coordination, and the clinical trial component is optional under this particular NOFO.
This NOFO is explicitly a single-source, non-competitive opportunity. NHLBI is announcing its intent to make a single award and is only inviting an application from one eligible applicant: Northwestern University. Even though the broader NIH eligibility list often includes a wide range of entities (such as universities, nonprofits, governments, and businesses), this specific announcement limits eligibility to Northwestern University for the purpose of renewing the existing Data Translation Center (DTC) that has been supporting HeartShare. Applications will still go through standard NIH peer review, and funding is contingent on the application being judged meritorious through that process.
The Data Translation Center is positioned as the coordinating and analytic hub for HeartShare 2.0. Its responsibilities include coordinating the overall program, continuing to oversee enrollment of a cohort of HFpEF patients, and managing the end-to-end handling of prospective deep phenotyping data. Deep phenotyping in this context generally refers to rich, multidimensional characterization of participants (often spanning clinical measures, imaging, biomarkers, physiologic signals, and other detailed assessments) collected prospectively to better capture heterogeneity within HFpEF. The DTC is also expected to curate these data, perform analyses to define and refine HFpEF subtypes, and translate findings into actionable insights that can inform trial-ready hypotheses and targeted interventions. In addition, the DTC will support planning, implementation, and data analysis for clinical trials that emerge from the program, helping ensure that trial design and evaluation are aligned with the phenotyping-derived subtype framework.
The NOFO is part of a larger coordinated set of HeartShare 2.0 funding announcements. A companion NOFO, RFA-HL-27-008, is intended to support Clinical Centers responsible for recruitment and follow-up of heart failure patients, as well as a Clinical Trial Center that will handle new clinical trial activities. In practical terms, this means HeartShare 2.0 is structured as a network: the Clinical Centers and Clinical Trial Center handle patient-facing recruitment, retention, follow-up, and trial operations, while the Data Translation Center provides cross-network coordination, data infrastructure, data curation, and advanced analytics to turn the incoming phenotyping information into subtype definitions and trial-supporting outputs.
Key administrative details include the funding opportunity number RFA-HL-27-009, the activity category of Health, and the CFDA/assistance listing number 93.837. The agency is NIH, and the posted closing date is 2026-07-09, with the opportunity created on 2026-05-19. Foreign organizations are not eligible to apply, foreign components are not allowed as defined by NIH policy, and while non-U.S. components of U.S. organizations are noted as eligible in general terms, this does not change the single-source limitation that only Northwestern University can apply for this specific award. Overall, the opportunity is designed to renew and strengthen the central data and translation engine of HeartShare so that deep phenotyping of HFpEF can be systematically converted into clinically meaningful subtypes and more personalized, testable treatment strategies within coordinated clinical trial efforts.Apply for RFA HL 27 009
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Single Source: HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials - Data Translation Center (U54 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.837.
- This funding opportunity was created on 2026-05-19.
- Applicants must submit their applications by 2026-07-09. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the title of this funding opportunity?
The funding opportunity is titled "Single Source: HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials - Data Translation Center (U54 Clinical Trial Optional)."
Which agency is offering this opportunity?
This is a National Institutes of Health (NIH) funding opportunity from the National Heart, Lung, and Blood Institute (NHLBI).
What is the funding opportunity number?
The funding opportunity number is RFA-HL-27-009.
What is the CFDA/Assistance Listing number?
The CFDA/Assistance Listing number is 93.837.
What is the purpose of HeartShare 2.0 under this NOFO?
The central goal is to refine heart failure with preserved ejection fraction (HFpEF) subtypes and identify treatment targets that can be used to design and run more personalized, subtype-informed clinical trials.
What does HFpEF mean in this context?
HFpEF refers to heart failure with preserved ejection fraction. In this program, HFpEF is the focus condition for prospective deep phenotyping to better capture heterogeneity and define clinically meaningful subtypes.
Is this a competitive funding opportunity?
No. This NOFO is explicitly a single-source, non-competitive opportunity. NHLBI is announcing its intent to make a single award.
Who is eligible to apply?
This specific announcement limits eligibility to one eligible applicant: Northwestern University. Even though NIH eligibility language can be broad in general, this NOFO only invites an application from Northwestern University to renew the existing Data Translation Center (DTC) supporting HeartShare.
Will the application still be peer reviewed?
Yes. Applications will still go through standard NIH peer review, and funding is contingent on the application being judged meritorious through that process.
What type of award mechanism is used?
The award mechanism is a U54 cooperative agreement.
What does a U54 cooperative agreement imply about NIH involvement?
A U54 cooperative agreement means NHLBI will have substantial involvement in project oversight and coordination, rather than serving only as a funder.
Are clinical trials required under this NOFO?
No. The clinical trial component is optional under this particular NOFO (U54 Clinical Trial Optional).
What is being supported or renewed through this NOFO?
This NOFO is designed to renew and strengthen the Data Translation Center (DTC) that has been supporting HeartShare, positioning it as the coordinating and analytic hub for HeartShare 2.0.
What is the Data Translation Center (DTC)?
The DTC is described as the coordinating and analytic hub for HeartShare 2.0. It provides overall program coordination, data infrastructure, data curation, and advanced analytics to translate deep phenotyping data into refined HFpEF subtypes and trial-supporting outputs.
What are the main responsibilities of the Data Translation Center?
Responsibilities include coordinating the overall program, continuing to oversee enrollment of a cohort of HFpEF patients, managing end-to-end handling of prospective deep phenotyping data, curating the data, analyzing the data to define and refine HFpEF subtypes, and translating findings into actionable insights that inform trial-ready hypotheses and targeted interventions.
What does "end-to-end handling" of data mean here?
Based on the description, it means the DTC is responsible for managing the full lifecycle of prospective deep phenotyping data, including collection coordination, curation, and analytic translation into outputs usable for subtype definitions and clinical trial planning and evaluation.
What is "deep phenotyping" in the context of this program?
Deep phenotyping refers to rich, multidimensional characterization of participants collected prospectively to capture heterogeneity within HFpEF. The description notes it often spans clinical measures, imaging, biomarkers, physiologic signals, and other detailed assessments.
How will the DTC use deep phenotyping data?
The DTC is expected to curate and analyze deep phenotyping data to define and refine HFpEF subtypes and translate findings into actionable insights that can inform subtype-informed, personalized clinical trial hypotheses and targeted interventions.
Does the DTC support clinical trials even if trials are optional under this NOFO?
Yes. The DTC is expected to support planning, implementation, and data analysis for clinical trials that emerge from the program, helping align trial design and evaluation with the phenotyping-derived subtype framework.
How does this NOFO fit into the broader HeartShare 2.0 program structure?
This NOFO is part of a coordinated set of HeartShare 2.0 funding announcements. HeartShare 2.0 is structured as a network: Clinical Centers and a Clinical Trial Center focus on recruitment, retention, follow-up, and trial operations, while the Data Translation Center provides cross-network coordination, data infrastructure, data curation, and analytics.
What is the companion funding opportunity mentioned, and what does it support?
A companion NOFO, RFA-HL-27-008, is intended to support Clinical Centers responsible for recruitment and follow-up of heart failure patients, as well as a Clinical Trial Center that will handle new clinical trial activities.
What is the activity category listed for this opportunity?
The activity category is Health.
When was the opportunity created, and what is the closing date?
The opportunity was created on 2026-05-19, and the posted closing date is 2026-07-09.
Are foreign organizations eligible to apply?
No. Foreign organizations are not eligible to apply.
Are foreign components allowed?
No. Foreign components are not allowed as defined by NIH policy.
Does the mention of non-U.S. components of U.S. organizations being eligible change who can apply?
No. While non-U.S. components of U.S. organizations are noted as eligible in general terms, the NOFO explicitly limits eligibility for this specific award to Northwestern University.
What is the overarching outcome this NOFO aims to enable?
The opportunity aims to ensure that prospective deep phenotyping of HFpEF can be systematically converted into clinically meaningful subtypes and more personalized, testable treatment strategies within coordinated clinical trial efforts.
Browse more opportunities from the same category: Health
Next opportunity: Native American Language Preservation and Maintenance-Esther Martinez Immersion
Previous opportunity: ROSS Rapid Response Program
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 27 009
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 27 009) also looked into and applied for these:
| Funding Opportunity |
|---|
| Biomedical Technology Optimization and Dissemination Center (BTOD) (RM1 - Clinical Trial Not Allowed) Apply for PAR 27 024 Funding Number: PAR 27 024 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA DK 27 136 Funding Number: RFA DK 27 136 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| ACL National Resource Center on Nutrition and Aging Apply for HHS 2026 ACL AOA PPNU 0003 Funding Number: HHS 2026 ACL AOA PPNU 0003 Agency: Administration for Community Living Category: Health Funding Amount: $1,014,596 |
| A Demonstration to Scale Innovative Person-Centered Approaches to Falls Prevention through Clinical-Community Partnerships Apply for HHS 2026 ACL CIP AAFP 0017 Funding Number: HHS 2026 ACL CIP AAFP 0017 Agency: Administration for Community Living Category: Health Funding Amount: $4,700,000 |
| Scaling Evidence-Based Falls Prevention Programs Apply for HHS 2026 ACL AOA FPSG 0004 Funding Number: HHS 2026 ACL AOA FPSG 0004 Agency: Administration for Community Living Category: Health Funding Amount: $740,162 |
| ACL National Falls Prevention Resource Center Apply for HHS 2026 ACL AOA FPSG 0005 Funding Number: HHS 2026 ACL AOA FPSG 0005 Agency: Administration for Community Living Category: Health Funding Amount: $2,500,000 |
| Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed) Apply for PAR 27 022 Funding Number: PAR 27 022 Agency: National Institutes of Health Category: Health Funding Amount: $5,000,000 |
| Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) Apply for RFA CA 27 002 Funding Number: RFA CA 27 002 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) Apply for RFA CA 27 001 Funding Number: RFA CA 27 001 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Kidney Precision Medicine Project Recruitment Sites (U01 Clinical Trial Not Allowed) Apply for RFA DK 27 301 Funding Number: RFA DK 27 301 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| Kidney Precision Medicine Project Tissue Interrogation Sites (U01 Clinical Trial Not Allowed) Apply for RFA DK 27 302 Funding Number: RFA DK 27 302 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Nutrition Obesity Research Centers (NORCs) (P30 Clinical Trial Optional) Apply for RFA DK 27 120 Funding Number: RFA DK 27 120 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed) Apply for RFA NS 27 011 Funding Number: RFA NS 27 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Science Track Award for Research Transition (START) Program (R03, Clinical Trial Optional) Apply for PAS 27 028 Funding Number: PAS 27 028 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Kidney Precision Medicine Project Central Hub (U24 Clinical Trial Not Allowed) Apply for RFA DK 27 303 Funding Number: RFA DK 27 303 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Growing Great Ideas: Research Education Course in Entrepreneurship and Product Development for Researchers Studying Drug Use, Drug Misuse, and Drug Addiction (UE5 Clinical Trial Not Allowed) Apply for RFA DA 27 007 Funding Number: RFA DA 27 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) (P30 - Clinical Trial Not Allowed) Apply for PAR 27 055 Funding Number: PAR 27 055 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Preventing global health threats by strengthening surveillance systems to accelerate outbreak detection, notification, and response Apply for CDC RFA JG 26 0113 Funding Number: CDC RFA JG 26 0113 Agency: Centers for Disease Control-GHC Category: Health Funding Amount: Case Dependent |
| Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed) Apply for RFA DK 27 108 Funding Number: RFA DK 27 108 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Kidney, Urologic, and Hematologic Diseases - Fostering the AdvanceMent of an Interactive Learning communitY - Coordinating Center (KUH-FAMILY) (U24- Clinical Trials Not Allowed) Apply for RFA DK 27 126 Funding Number: RFA DK 27 126 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 27 009", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.